Corbus Pharmaceuticals Holdings, Inc. (CRBP)
NASDAQ: CRBP · Real-Time Price · USD
9.82
-0.26 (-2.58%)
At close: Apr 28, 2026, 4:00 PM EDT
10.17
+0.35 (3.56%)
Pre-market: Apr 29, 2026, 6:03 AM EDT
Company Description
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity.
Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity.
The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.
Corbus Pharmaceuticals Holdings, Inc.
| Country | United States |
| Founded | 2009 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 36 |
| CEO | Yuval Cohen |
Contact Details
Address: 500 River Ridge Drive Norwood, Massachusetts 02062 United States | |
| Phone | 617 963 0100 |
| Website | corbuspharma.com |
Stock Details
| Ticker Symbol | CRBP |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001595097 |
| CUSIP Number | 21833P103 |
| ISIN Number | US21833P3010 |
| Employer ID | 46-4348039 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Yuval Cohen Ph.D. | Chief Executive Officer and Director |
| Sean F. Moran CPA, M.B.A. | Chief Financial Officer |
| Dr. Dominic Smethurst M.A., M.D. | Chief Medical Officer |
| Dr. Ian Hodgson B.Sc., Ph.D. | Chief Operating Officer |
| G. Scott Goeken J.D., M.S. | General Counsel and Corporate Secretary |
| Christina Bertsch M.A. | Vice President of Human Resources |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 16, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 16, 2026 | 8-K | Current Report |
| Apr 14, 2026 | 8-K | Current Report |
| Apr 7, 2026 | 8-K | Current Report |
| Apr 2, 2026 | ARS | Filing |
| Apr 2, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 2, 2026 | DEF 14A | Other definitive proxy statements |
| Mar 25, 2026 | 424B3 | Prospectus |
| Mar 20, 2026 | EFFECT | Notice of Effectiveness |
| Mar 11, 2026 | S-3 | Registration statement under Securities Act of 1933 |